In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Insulet sells $120.8mm of debt

Executive Summary

Insulet Corp., maker of the OmniPod insulin management system for diabetics, has netted $120.8mm through the private placement of 3.75% five-year convertible senior notes. The notes convert into 38.2 shares per $1k in principal at $26.20 each. Some of the funds may be used to repurchase $70mm in notes that are due in 2013.
Deal Industry
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Convertible Debt

Related Companies